Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Elisabet Cruces"'
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 55(1)
Sixty-four new drugs and biologics reached their first global markets in 2018, the greatest number in at least a decade. In addition, 19 important new line extensions (new indications, new combinations or new formulations of previously marketed drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e47e8c01ddbbcee872872f8309526e
https://pubmed.ncbi.nlm.nih.gov/30740611
https://pubmed.ncbi.nlm.nih.gov/30740611
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 54(2)
This eagle's-eye overview of the drug industry in 2017 provides insight into some of last year's top stories, including the growing opioid crisis affecting the U.S. and other developed countries and the 2017-2018 influenza epidemic, with a spotlight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1ec166d961ded5addf8852e3ed7ea77
https://pubmed.ncbi.nlm.nih.gov/29637939
https://pubmed.ncbi.nlm.nih.gov/29637939
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 53(2)
This eagle's-eye overview of the drug industry in 2016 provides insight into some of last year's top stories, including disease outbreaks that drove R&D, orphan drug development, pipeline attrition, drug pricing, and the ongoing movement in M&A. We a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8378087b34bedb5858cad2eb5efc6494
https://pubmed.ncbi.nlm.nih.gov/28387389
https://pubmed.ncbi.nlm.nih.gov/28387389
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 52(2)
This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2501ea498dc63b5ed716d11b70eb63b2
https://pubmed.ncbi.nlm.nih.gov/27092342
https://pubmed.ncbi.nlm.nih.gov/27092342
Autor:
Elisabet Cruces
Publikováno v:
Drugs of Today. 54:381
During the first quarter of 2018, Cortellis Competitive Intelligence registered 879 new deals (excluding mergers and acquisitions) with a total disclosed deal value of approximately USD 35.2 billion as part of its ongoing coverage of licensing activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4e6d5a2bfa47857899d63f372cbc7fb
https://doi.org/10.1358/dot.2018.54.6.2856494
https://doi.org/10.1358/dot.2018.54.6.2856494
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 51(2)
2014 was a year of continued high activity in the pharma and biotech industry, as evidenced in part I of this annual two-part review article published last month in this journal (1). As of December 23, 2014, a total of 55 new chemical and biological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f1dddbca36a4df7bb002338fed50f9
https://pubmed.ncbi.nlm.nih.gov/25756068
https://pubmed.ncbi.nlm.nih.gov/25756068
Autor:
Elisabet Cruces
Publikováno v:
Drugs of Today. 53:357
During the first quarter of 2017, Cortellis Competitive Intelligence had 1,073 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This meant a slight increase on the last quarter (1,022) and a similar volume on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5199057f7485492295223ffbfdc994
https://doi.org/10.1358/dot.2017.53.6.2662982
https://doi.org/10.1358/dot.2017.53.6.2662982
Publikováno v:
Drugs of Today. 53:77
Nearly 90 new drugs and biologics, including important new line extensions, were approved or launched for the first time globally in 2016, a comparatively lower number with respect to previous years. Forty-four new drugs and biologics reached their f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad1d0dd5b1c41787bc49c7cd362fd4c
https://doi.org/10.1358/dot.2017.53.1.2584699
https://doi.org/10.1358/dot.2017.53.1.2584699
Autor:
D. Navarro, Charlotte Jago, Coia Dulsat, M. Tracy, Ann I. Graul, Xavier Rabasseda, Elisabet Cruces
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 49(2)
As highlighted in the first part of this review published last month, the year 2012 saw the approval of a remarkable number of new drugs, and among the new drugs reaching the market, a significant proportion were orphan drugs developed for treating l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75bb4f8f8262211413fc41cda153095
https://pubmed.ncbi.nlm.nih.gov/23462626
https://pubmed.ncbi.nlm.nih.gov/23462626
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 49(1)
Thirty-seven new launches are considered in the first part of this annual review article, including 36 drugs and biologics that reached their first markets worldwide in 2012 and one additional drug that was launched at the end of December 2011. In ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6263fc6cbc3aed4005bbdda37c5752a
https://pubmed.ncbi.nlm.nih.gov/23362494
https://pubmed.ncbi.nlm.nih.gov/23362494